Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net (Tables)

Intangibles, net (Tables)

3 Months Ended

Mar. 31, 2021

The table below provides a summary of the Journey intangible assets as of March 31, 2021 and December 31, 2020, respectively:


	Estimated Useful
($ in thousands)	Lives (Years)	March 31, 2021		December 31, 2020
		(Unaudited)
Total Intangible assets – asset purchases	3 to 7	$	19,003	$	18,606
Accumulated amortization			(4,561)		(3,977)
Net intangible assets		$	14,442	$	14,629

Schedule of JMC recognized expense related to its product licenses

The table below provides a summary for the three months ended March 31, 2021, of Journey’s recognized expense related to its product licenses, which was recorded in costs of goods sold on the Condensed Consolidated Statement of Operations:


	Intangible
($ in thousands)	Assets, Net
Beginning balance at January 1, 2021	$	14,629
Additions:
Exelderm milestone		397
Amortization expense		(584)
Ending balance at March 31, 2021	$	14,442

Schedule of future amortization of intangible assets

The future amortization of these intangible assets is as follows:


							Total
($ in thousands)	Ximino®		Exelderm®		Accutane®		Amortization
Nine Months Ended December 31, 2021	$	764	$	417	$	709	$	1,890
Year Ended December 31, 2022		1,019		—		946		1,965
Year Ended December 31, 2023		1,019		—		945		1,964
Year Ended December 31, 2024		1,019		—		946		1,965
Year Ended December 31, 2025		1,019		—		945		1,964
Thereafter		595		—		158		753
Sub-total	$	5,435	$	417	$	4,649	$	10,501
Assets not yet placed in service:
Anti-itch product license acquisition (amortization commencing second half of 2021)		—		—		—		3,941
Total	$	5,435	$	417	$	4,649	$	14,442